Alveolar echinococcosis of the liver: a single center experience.

Authors: Dulger AC,Esen R,Begenik H,Aytemiz E,Demirtas L,Aslan M,
Address: Yuzuncu Yil University, Medical Faculty, Department of Gastroenterology, Van, Turkey.
Journal: Pol Arch Med Wewn.

Publication: 2012;122(4):133-8. Epub 2012 Mar 13.

abstract

INTRODUCTION:

In humans, Alveolar echinococcosis (AE) of the liver is caused by canine tapeworm called Echinococcus multilocularis. The disease is most prevalent in the northern hemisphere and in the eastern part of Turkey.

OBJECTIVES:

The aim of the study was to review the natural history of AE and its clinical and radiological features.

PATIENTS AND METHODS:

The retrospective study involved 23 patients (10 men, 13 women), aged 34-75 years with AE who had been referred to our liver disease clinic in the past 4 years. Only patients with pathologically proven AE were included in the study. The sociodemographic, clinical, and radiological features of AE were also evaluated.

RESULTS:

The main laboratory characteristics of AE included mild eosinophilic leukocytosis with hypergammaglobulinemia, elevated C-reactive protein levels, near-normal liver transaminases, and increased levels of cholestatic enzymes and immunoglobulin E. Eight patients (35%) had hepatitis B e antigen-negative hepatitis B infection. Budd-Chiari syndrome was identified in 3 of 23 patients (13%). Eighty-three percent of the patients had a seropositive test result for AE, and approximately one-third of the patients had distant metastasis. Surgical treatment was administered in 4 patients. Four patients died due to complications during follow-up.

CONCLUSIONS:

Patients with AE have numerous complications and advanced disease at the time of diagnosis. The clinical picture of AE comprises a number of hepatic and extrahepatic disturbances related both to destructive and mass effects of the tapeworm.

Related Articles
Usefulness of recombinant Em18-ELISA to evaluate efficacy of treatment in patients with alveolar echinococcosis.
J Gastroenterol. 2005
Usefulness of recombinant Em18-ELISA to evaluate efficacy of treatment in patients with alveolar echinococcosis.
Fujimoto Y, Ito A, Ishikawa Y, Inoue M, Suzuki Y, Ohhira M, Ohtake T, Kohgo Y. J Gastroenterol. 2005 Apr; 40(4):426-31.
Indications and results of liver transplantation for Echinococcus alveolar infection: an overview.
Langenbecks Arch Surg. 2003
Indications and results of liver transplantation for Echinococcus alveolar infection: an overview.
Bresson-Hadni S, Koch S, Miguet JP, Gillet M, Mantion GA, Heyd B, Vuitton DA, European group of clinicians. Langenbecks Arch Surg. 2003 Sep; 388(4):231-8. Epub 2003 Aug 5.
[A case of alveolar echinococcosis in Malatya province].
Turkiye Parazitol Derg. 2008
[A case of alveolar echinococcosis in Malatya province].
Atambay M, Karaman U, Miman O, Karadağ N, Söğütlü G, Daldal N. Turkiye Parazitol Derg. 2008; 32(2):164-6.
Review Molecular survival strategies of Echinococcus multilocularis in the murine host.
Parasitol Int. 2006
Review Molecular survival strategies of Echinococcus multilocularis in the murine host.
Gottstein B, Haag K, Walker M, Matsumoto J, Mejri N, Hemphill A. Parasitol Int. 2006; 55 Suppl:S45-9. Epub 2005 Dec 13.
Review Development of Em18-immunoblot and Em18-ELISA for specific diagnosis of alveolar echinococcosis.
Acta Trop. 2003
Review Development of Em18-immunoblot and Em18-ELISA for specific diagnosis of alveolar echinococcosis.
Ito A, Sako Y, Yamasaki H, Mamuti W, Nakaya K, Nakao M, Ishikawa Y. Acta Trop. 2003 Feb; 85(2):173-82.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.